Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes.

Hinshaw L, Schiavon M, Dadlani V, Mallad A, Dalla Man C, Bharucha A, Basu R, Geske JR, Carter RE, Cobelli C, Basu A, Kudva YC

The Journal of clinical endocrinology and metabolism1 Mar 2016Cited by 25 (Europe PMC)

PMID26930181PMCIDPMC4870844DOI10.1210/jc.2015-3952PepBankPUB-26930181

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide lowered meal glucose appearance compared with no pramlintide.
In plain wordsIn people with type 1 diabetes, pramlintide reduced glucose entry from meals compared with no pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMeal glucose appearance rate
Study
n = 12
Comparator
without pramlintide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
iAUC difference
1196.2 μM/kg fat free mass
without versus with pramlintide
Source sentences
Summary
meal rate of glucose appearance was lower (difference in iAUC: 1196.2 μM/kg fat free mass [FFM]; P = .0316)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center, inpatient, randomized, crossover study.PatientsTwelve patients with T1D who completed the study were analyzed.InterventionsSubjects were studied on two occasions with or without pramlintide.
Report a problemFND-2693018104
02HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, endogenous glucose production did not differ with versus without pramlintide.
In plain wordsIn people with type 1 diabetes, glucose production did not differ with versus without pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeEndogenous glucose production
Study
n = 12
Comparator
without pramlintide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
iAUC difference
−105.5 μM/kg FFM
without versus with pramlintide
Source sentences
Summary
endogenous glucose production was not different (difference in iAUC: -105.5 μM/kg FFM; P = .5842)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center, inpatient, randomized, crossover study.PatientsTwelve patients with T1D who completed the study were analyzed.InterventionsSubjects were studied on two occasions with or without pramlintide.
Report a problemFND-2693018105
03HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide lowered glucose disappearance compared with no pramlintide.
In plain wordsIn people with type 1 diabetes, pramlintide reduced glucose removal from blood compared with no pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseGlucose disappearance rate
Study
n = 12
Comparator
without pramlintide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
iAUC difference
1494.2 μM/kg FFM
without versus with pramlintide
Source sentences
Summary
rate of glucose disappearance was lower (difference in iAUC: 1494.2 μM/kg FFM; P = .0083)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center, inpatient, randomized, crossover study.PatientsTwelve patients with T1D who completed the study were analyzed.InterventionsSubjects were studied on two occasions with or without pramlintide.
Report a problemFND-2693018106
04HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, insulin sensitivity did not differ with versus without pramlintide.
In plain wordsIn people with type 1 diabetes, insulin sensitivity did not differ with versus without pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeInsulin sensitivity
Study
n = 12
Comparator
without pramlintide
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
SI and liver insulin sensitivity were not different between study visits (P > .05).
2 context sentences(design, population, supporting numbers)
Summary · context
Glucose turnover and SI were the main outcome measures.
Summary · context
This was a single-center, inpatient, randomized, crossover study.PatientsTwelve patients with T1D who completed the study were analyzed.InterventionsSubjects were studied on two occasions with or without pramlintide.
Report a problemFND-2693018107
05HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, pramlintide reduced postprandial glucose excursions compared with no pramlintide.
In plain wordsIn people with type 1 diabetes, pramlintide reduced glucose rises after meals compared with no pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose excursions
Study
n = 12
Comparator
without pramlintide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
iAUC difference
444 mMmin
without versus with pramlintide
Source sentences
Summary
plasma glucose excursions were reduced (difference in incremental area under the curve [iAUC], 444.0 mMmin, P = .0003)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center, inpatient, randomized, crossover study.PatientsTwelve patients with T1D who completed the study were analyzed.InterventionsSubjects were studied on two occasions with or without pramlintide.
Report a problemFND-2693018101
06HumanRandomized controlled trialActivity measurement
In patients with type 1 diabetes, pramlintide lowered postprandial plasma insulin compared with no pramlintide.
In plain wordsIn people with type 1 diabetes, pramlintide lowered insulin after meals compared with no pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePlasma insulin
Study
n = 12
Comparator
without pramlintide
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated
Measurements
iAUC difference
7642 pMmin
without versus with pramlintide
Source sentences
Summary
plasma insulin concentrations were lower (difference in iAUC, 7642.0 pMmin; P = .0099)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center, inpatient, randomized, crossover study.PatientsTwelve patients with T1D who completed the study were analyzed.InterventionsSubjects were studied on two occasions with or without pramlintide.
Report a problemFND-2693018102
07HumanRandomized controlled trialActivity measurement
In patients with type 1 diabetes, pramlintide lowered glucagon excursions compared with no pramlintide.
In plain wordsIn people with type 1 diabetes, pramlintide reduced glucagon rises compared with no pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePlasma glucagon excursions
Study
n = 12
Comparator
without pramlintide
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated
Measurements
iAUC difference
1730.6 pg/mlmin
without versus with pramlintide
Source sentences
Summary
plasma glucagon excursions were lower (difference in iAUC, 1730.6 pg/mlmin; P = .0147)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center, inpatient, randomized, crossover study.PatientsTwelve patients with T1D who completed the study were analyzed.InterventionsSubjects were studied on two occasions with or without pramlintide.
Report a problemFND-2693018103
08HumanRandomized controlled trialEfficacy outcome
In patients with type 1 diabetes, liver insulin sensitivity did not differ with versus without pramlintide.
In plain wordsIn people with type 1 diabetes, liver insulin sensitivity did not differ with versus without pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeLiver insulin sensitivity
Study
n = 12
Comparator
without pramlintide
Outcome group
Glycemic control · Liver
Studied dose
Dose not stated
Source sentences
Summary
SI and liver insulin sensitivity were not different between study visits (P > .05).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a single-center, inpatient, randomized, crossover study.PatientsTwelve patients with T1D who completed the study were analyzed.InterventionsSubjects were studied on two occasions with or without pramlintide.
Report a problemFND-2693018108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.